Vaxcyte, Inc. (PCVX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vaxcyte, Inc. entered into an underwriting agreement with BofA Securities, Inc. and other representatives for the sale of 10,937,500 common stock shares and pre-funded warrants to purchase an additional 781,250 shares. The shares were priced at $64.00 each and the pre-funded warrants at $63.999, with an additional option for underwriters to purchase up to 1,757,812 more shares. The underwriters exercised this option in full, bringing Vaxcyte’s expected net proceeds from the offering to approximately $816.5 million. The closing of the offering is anticipated around February 2, 2024, and it is made under Vaxcyte’s effective registration statement.
For further insights into PCVX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.